Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
The CSDD is a clinician-rated depression scale designed for people with dementia, combining caregiver interview and direct patient observation. It includes 19 items across mood, behavior, physical signs, cyclic functions, and ideational disturbance domains (0-2 each; total 0-38).
Formula: CSDD total = sum of 19 items scored 0-2 (range 0-38).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The CSDD begins with a structured interview with a knowledgeable informant — typically the patient's primary caregiver, family member, or nursing staff member who regularly observes the patient. The clinician asks about 19 specific depressive symptoms observed over the past week, covering mood-related signs (anxiety, sadness, lack of reactivity, irritability), behavioral disturbances (agitation, retardation, multiple physical complaints, loss of interest), physical signs (appetite loss, weight loss, energy loss), cyclic functions (diurnal mood variation, sleep difficulty, insomnia, hypersomnia), and ideational disturbance (suicidal ideation, poor self-esteem, pessimism, mood-congruent delusions). Each item is rated 0 (absent), 1 (mild/intermittent), or 2 (severe/frequent), with 'a' (unable to evaluate) for ambiguous items.
After the caregiver interview, directly observe and briefly interview the patient. The purpose is to observe for behavioral signs of depression directly (psychomotor retardation or agitation, sad facies, lack of spontaneity) and to detect any discordance between caregiver report and patient presentation. In patients with severe dementia who cannot respond to direct questioning, this step is primarily observational. The clinician synthesizes both sources of information to finalize ratings, giving weight to caregiver report where patient self-report is unreliable.
Sum all 19 item scores to produce a total from 0 to 38. Standard interpretation bands are: 0-7 = no significant depression; 8-11 = probable mild depression; 12 or above = probable major depression. The CSDD total should be interpreted alongside the complete clinical picture, including functional status, medication history, recent losses, medical comorbidities, and prior psychiatric history. A score of 12 or above warrants further diagnostic evaluation for major depressive disorder and consideration of antidepressant treatment, non-pharmacological mood interventions, and caregiver support.
Geriatricians, geriatric psychiatrists, neuropsychologists
The CSDD is a preferred depression screening tool in memory clinic settings where patients with cognitive impairment cannot reliably self-report mood symptoms. Standard self-report tools such as PHQ-9 and GDS are often underperformed in moderate-to-severe dementia because patients cannot accurately recall or reflect on their emotional states. The CSDD's combination of caregiver interview and direct observation provides a more reliable and sensitive assessment of depression in this population.
Geriatricians, primary care physicians, nurse practitioners
The CSDD is included as a mood assessment component in comprehensive geriatric assessments, providing a validated, structured alternative to generic depression tools in patients with dementia. Depressive symptoms are present in 30-50% of people with Alzheimer's disease and are often undertreated. Early detection using the CSDD enables timely initiation of antidepressant therapy (where indicated), non-pharmacological interventions, and caregiver education about the behavioral manifestations of depression in dementia.
Long-term care nurses, nursing home physicians, social workers
In residential aged care facilities, the CSDD can be incorporated into routine assessment cycles for residents with dementia to detect incident depression or monitor response to treatment. Depression in nursing home residents with dementia is strongly associated with behavioral disturbance, reduced food intake, falls, and caregiver burden. Regular CSDD assessments enable early identification and treatment, potentially reducing these downstream complications.
Psychiatrists, geriatricians, pharmacists, clinical nurses
The CSDD is used as an outcome measure for antidepressant treatment in dementia, providing a structured baseline and follow-up assessment that tracks treatment response. A reduction of 4 or more points from baseline is generally considered clinically meaningful. Serial CSDD scores over 6-12 weeks of treatment provide documentation of response, help guide dose adjustments, and support decisions about whether to continue, change, or discontinue antidepressant therapy.
Geriatric psychiatrists, behavioral care specialists, dementia consultants
Depression in dementia can present predominantly as behavioral disturbance (agitation, irritability, refusal of care, social withdrawal, reduced appetite) rather than classic sad mood. The CSDD's behavioral disturbance domain and ideational disturbance items help clinicians differentiate depressive behavioral disturbance from primary agitation syndromes, delirium, or pain-related behavior — all of which require different management approaches.
The quality of the CSDD is entirely dependent on the quality of the caregiver informant. Choose the staff member or family member who spends the most time with the patient and who can reliably report on mood and behavior over the past week. Staff who rotate infrequently or family members who visit only occasionally may not have observed the relevant behaviors.
Apathy and depression frequently co-occur in dementia but have different clinical implications and management approaches. Apathy presents primarily as reduced motivation, engagement, and initiative without the mood, cognitive, and vegetative features of depression. The CSDD's lack-of-reactivity item is important for this distinction. Patients with pure apathy (without emotional distress, negative ideation, or sleep/appetite changes) may score low on CSDD despite appearing withdrawn, while those with genuine depression accumulate scores across multiple domains.
When there is insufficient information from either the caregiver interview or direct observation to score an item — for example, 'diurnal mood variation' when the caregiver only sees the patient in the afternoon — score it as 'a' (unable to evaluate) rather than defaulting to 0. This avoids systematically underestimating CSDD scores when information is incomplete.
The ideational disturbance domain includes mood-congruent delusions (e.g., beliefs of poverty, guilt, terminal illness). When present, these indicate severe depressive phenomenology requiring urgent psychiatric review. A patient with dementia who has developed mood-congruent delusions alongside other depressive features represents a high-risk presentation requiring prompt antidepressant consideration and psychiatric input.
Several CSDD items (appetite loss, energy loss, sleep disturbance) can be driven by undertreated medical comorbidities rather than depression. Before attributing high CSDD scores to a primary mood disorder, ensure that pain, infection, thyroid disease, anemia, and other medical contributors have been identified and treated. Reassessing the CSDD after medical optimization helps clarify how much residual mood disturbance warrants specific psychiatric treatment.
Clinicians sometimes try to map CSDD scores onto PHQ-9 equivalents. The instruments are not directly comparable — they assess different symptom domains, use different rating scales, and draw on different informant sources. The CSDD score should be interpreted within its own normative framework (0-7 minimal, 8-11 probable mild, 12+ probable major depression) rather than being converted or compared to self-report scale equivalents.
CSDD is most valuable when used serially. Establish a baseline before initiating antidepressant therapy, reassess at 4-6 weeks, and again at 12 weeks. A reduction of 4 or more points represents a clinically meaningful response. Lack of improvement after adequate antidepressant trial at therapeutic dose warrants psychiatric reassessment.
The CSDD was designed and validated by Alexopoulos et al. (1988) specifically for depression detection in dementia. It remains the gold-standard instrument for structured depression assessment in patients with moderate-to-severe dementia and is widely used in geriatric psychiatry, memory clinics, and long-term care settings. Score bands: 0-7 minimal, 8-11 probable mild depression, 12+ probable major depression.
Higher CSDD totals indicate greater depressive symptom burden in a dementia context and support targeted mood-focused clinical follow-up.
Use when depression is suspected in patients with dementia or significant cognitive impairment where standard self-report tools may underperform.
Scores depend on quality of collateral history and observer training; overlap with apathy, delirium, and medical illness can confound interpretation.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Screen depressive symptoms in older adults using the 15-item GDS-15 yes/no questionnaire.
OpenMental HealthFree PHQ-9 depression screening questionnaire. Take the Patient Health Questionnaire-9 to assess depression severity with instant scoring and interpretation. Also screen for anxiety with [GAD-7](/tools/gad7).
OpenMental HealthInterpret Montreal Cognitive Assessment (MoCA) scores. The leading cognitive screening tool for mild cognitive impairment and dementia.
OpenGeriatricsClassify SLUMS cognitive-screen totals (0-30) to support triage for fuller neurocognitive evaluation.
Open